Steroid Treatment After Resuscitated Out-of-Hospital Cardiac Arrest (STEROHCA)

March 27, 2023 updated by: Christian Hassager

Steroid Treatment as Anti-inflammatory and Neuroprotective Agent Following Out-of-Hospital Cardiac Arrest. A Randomized Trial

Comatose patients resuscitated from Out-of-Hospital Cardiac Arrest (OHCA) often develop a complicated systemic inflammatory response and have a poor prognosis with neurological damage being the most common cause of death. This study will investigate the anti-inflammatory and neuroprotective effect of early treatment with the glucocorticoid methylprednisolone measured by interleukin-6 and neuron-specific enolase levels in resuscitated comatose OHCA-patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

BACKGROUND:

Each year approximately 5400 individuals suffer from Out-of-Hospital Cardiac Arrest (OHCA) in Denmark and despite an improved prognosis 30-day mortality is around 90%. For OHCA patients resuscitated successfully and admitted to an Intensive Care Unit (ICU) the 30-day mortality remains higher than 50% due to a complicated systemic response, referred to as the Post Cardiac Arrest Syndrome (PCAS). PCAS consists of four interacting components: 1) ischemic/reperfusion brain injury, 2) myocardial dysfunction, 3) a systemic inflammatory response and 4) persistent stress from the triggering cause of the cardiac arrest, e.g. acute myocardial infarction. PCAS progresses during the first 1-2 days following resuscitated cardiac arrest, and the treatment aims to reduce neurologic injury by cooling the patient to 33-36° C, circulatory support with vasopressors, inotropics or mechanical devices as well as identification and treatment of reversible causes to the cardiac arrest, e.g. acute revascularization of an AMI.

Several studies have shown that the systemic inflammatory response is associated with a high risk of poor outcome following OHCA. Inflammatory markers associated with poor outcome include interleukin (IL) 6, high sensitivity C-reactive protein (hsCRP), leucocytes, IL-1b, IL-10, IL-13, tumor necrosis factor alpha (TNF-alpha) and procalcitonin. Despite of this, there is no specific treatment that addresses this complicated and life-threatening systemic response, and guidelines remain inconclusive in this field.

Anoxic irreversible brain injury remains the leading cause of death following resuscitated OHCA. The complex mechanism is one of the components in the PCAS and is thought to develop due to neuron apoptosis and reperfusion/ischemic injury. Further, the biomarker neuron-specific enolase (NSE) is correlated to neuron damage in the blood stream and has a strong predictive value for poor outcome following OHCA. Inhibiting the causes of the systemic inflammatory response and thereby potentially the brain injury in the very early stages following resuscitation from OHCA may therefore be key to optimizing post-cardiac arrest care.

Following resuscitated OHCA, the function of the adrenal gland is compromised due to global ischemia and reduced levels of the hormone steroid, glucocorticoid, are produced. Glucocorticoid has an important role in several physiologic processes including an anti-inflammatory systemic response. As a result, resuscitated cardiac arrest patients are affected by a severe inflammatory response, while the natural defense mechanism of the body to modulate inflammation is suppressed. Systemic treatment with steroids serves as an anti-inflammatory mediator and counteracts acute microcirculation injury and free radical formation, resulting in diminished vasodilation and reduction of edema, e.g. brain edema. Two small studies have shown signs of improved survival and neurologic outcome among patients who was given injections with glucocorticoids after in-hospital cardiac arrest. The incidence of adverse events was not higher in patients receiving glucocorticoids. Long-term treatment with glucocorticoids is associated with a series of side effects, whereas short-term treatment only has a few side effects. Systemic treatment with glucocorticoids could therefore be an important and safe factor in the treatment of resuscitated cardiac arrest patients that could potentially improve survival and neurological outcome.

Methylprednisolone and other glucocorticoids are used in pulse doses (>250 mg prednisolone equivalent a day) in various acute immunologically mediated conditions/diseases such as organ transplantation to prevent organ rejection and certain rheumatic diseases with acute deterioration. All these conditions are associated with a severe inflammatory response, as seen in PCAS, and therefore methylprednisolone doses as high as 30 mg/kg (equivalent of 2.1 g for a person weighing 70 kg) are used in pulse therapy to obtain an adequate response and effect. Further, the advantage of pulse dose glucocorticoid treatment is better efficacy, but also a decrease in side effects due to a reduced need for longer lasting therapy exceeding days or weeks. The literature reports of possible cardiovascular side effects as bradycardia and arrhythmias associated to infusion of pulse doses of methylprednisolone/glucocorticoids if given within a short period of time, but the evidence is limited and not well supported. The Danish summary of product characteristics recommends an initial infusion of Solu-Medrol to be administered over a period of at least five minutes.

Based on the above knowledge the intervention in this study is 250 mg of methylprednisolone administered intravenously as a bolus infusion over five minutes.

In summary, following resuscitated OHCA, PCAS, a severe and life-threatening condition, is often developed. PCAS is associated with increased mortality and poor neurological outcome. Inhibition of this inflammatory response may have an important, yet relatively unknown, role in post-cardiac arrest care.

HYPOTHESIS:

Bolus infusion of 250 mg methylprednisolone in the pre-hospital setting will inhibit the systemic inflammatory response and minimize the degree of neurological injury in comatose, resuscitated Out-of-Hospital Cardiac Arrest (OHCA) patients.

SAMPLE SIZE:

The trial is powered at the co-primary endpoint. The investigators chose a priori to power the trial at the 'weakest' of the two endpoints, ensuring a sufficient power for both endpoints. As the investigators were not able to find data regarding the effect of methylprednisolone on IL-6 levels or NSE levels from OHCA admission, the trial was powered towards a single measurement drawn 48 hours after admission. In 171 patients from the investigators institution the mean (logarithmically transformed to approximate normal distribution) IL-6 level after 48 hours from admission was 4.19±1.27 (unpublished data). The investigators assumed that methylprednisolone would reduce the IL-6 level by 20%. With an α-level of 0.025, the trial would achieve a power of 0.90 if 112 patients were included. The mean (logarithmically transformed to approximate normal distribution) NSE level after 48 hours was 3.21±0.96 after 48 hours from admission (unpublished data). The investigators assumed that methylprednisolone would reduce the NSE level by 20%. With an α-level of 0.025, the trial would achieve a power of 0.90 if 114 patients were included. The investigators aimed to include 120 patients, to adjust for missingness due to withdrawn consent. Further, since a proportion of the patients were expected to die before complete assessment of the co-primary endpoint (i.e. blood sampling at 72 hours), randomization of patients will continue until a total of 120 patients have survived to blood sampling at 72 hours.

Study Type

Interventional

Enrollment (Actual)

158

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
      • Copenhagen, Denmark, 2100
        • Rigshospitalet
      • Gentofte, Denmark, 2820
        • Gentofte Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age ≥18 years
  2. OHCA of presumed cardiac cause
  3. Unconsciousness (GCS ≤8) upon pre-hospital randomization
  4. Sustained ROSC for at least 5 minutes
  5. Randomization and start of study medicine infusion within 30 minutes of sustained ROSC.

Exclusion Criteria:

  1. Advanced life support termination-of-resuscitation exclusion criteria
  2. Asystole as primary ECG rhythm
  3. Women of childbearing capacity
  4. Known therapy limitation
  5. Known allergy to methylprednisolone
  6. Known pre-arrest modified Rankin Scale (mRS) score of 4-5
  7. Temperature upon randomization <30° C
  8. >30 minutes to sustained ROSC.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Isotonic saline
A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
Drug: Isotonic saline
A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
Other Names:
  • Placebo
Active Comparator: Methylprednisolone
A five minutes bolus infusion of 250 mg (4 mL) methylprednisolone to inhibit inflammatory and neurological damage following resuscitated out-of-hospital cardiac arrest. The infusion of methylprednisolone will be given following five minutes of sustainable ROSC in the prehospital setting.
Drug: Methylprednisolone
A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.
Other Names:
  • Solu-Medrol

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Concentration of IL-6
Time Frame: Daily measurements from admission to 72 hours after admission
Interleukin 6 (ng/L)
Daily measurements from admission to 72 hours after admission
Concentration of NSE
Time Frame: Daily measurements from admission to 72 hours after admission
Neuron-specific-enolase (ng/L)
Daily measurements from admission to 72 hours after admission

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Markers of inflammation, biomarkers
Time Frame: Daily measurements the first three days following admission
High sensitivity C-reactive protein (hsCRP, mg/L) and plasma cytokine levels exemplified by IL-6 (ng/L)
Daily measurements the first three days following admission
Markers of inflammation, cell count
Time Frame: Daily measurements the first three days following admission
Leucocyte- and differential count (thousand cells/µL)
Daily measurements the first three days following admission
Markers of kidney and hepatic injury
Time Frame: Daily measurements the first three days following admission
Creatinine, ALAT, ASAT, BF and bilirubin (all in mg/L)
Daily measurements the first three days following admission
Marker of the coagulation system, biomarker
Time Frame: Plasma fibrinogen the first three days from admission
Plasma fibrinogen (mg/L)
Plasma fibrinogen the first three days from admission
Marker of the coagulation system, functional analysis
Time Frame: Thromboelastography at admission and at 48 hours
Thromboelastography (TEG, measured in minutes)
Thromboelastography at admission and at 48 hours
Hemodynamics, Swan-Ganz catheter
Time Frame: Daily Swan-Ganz catheter measurements the first five days from admission
Measurements on Swan-Ganz catheter (CVP, PAP, PCWP - all in mmHg)
Daily Swan-Ganz catheter measurements the first five days from admission
Hemodynamics, arterial blood gasses (Lactate)
Time Frame: Arterial blood gasses bihourly the first 36 hours
Arterial blood gasses (Lactate in mmol/L)
Arterial blood gasses bihourly the first 36 hours
Hemodynamics, arterial blood gasses
Time Frame: Arterial blood gasses bihourly the first 36 hours
Arterial blood gasses (PaO2 and PaCO2 in kPa)
Arterial blood gasses bihourly the first 36 hours
Neuroprotection, biomarkers
Time Frame: Biomarkers the first three days from admission
Biomarkers TAU, NFL, NFM, NFH and GFAP (all in mmol/L)
Biomarkers the first three days from admission
Cardiac protection, biomarkers
Time Frame: Biomarkers the first three days from admission
TnT, TnI and CKMB (all in mmol/L).
Biomarkers the first three days from admission
Clinical endpoint, survival
Time Frame: 180 days following discharge
Survival (yes/no, register based data from "The Medical Register of Births and Deaths" in Denmark)
180 days following discharge
Clinical endpoint, neurological outcome by mRS score
Time Frame: After five days of admission and at 30- and 180- days following discharge
Neurological outcome (modified Rankin Scale score, 0-6 symptom scale with higher scores indicating more severe symptoms)
After five days of admission and at 30- and 180- days following discharge
Safety, adverse events
Time Frame: From admission till 7 days following admission
Cumulated incidence of adverse events
From admission till 7 days following admission

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Christian Hassager

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 10, 2020

Primary Completion (Actual)

July 15, 2022

Study Completion (Actual)

February 28, 2023

Study Registration Dates

First Submitted

October 12, 2020

First Submitted That Met QC Criteria

November 5, 2020

First Posted (Actual)

November 12, 2020

Study Record Updates

Last Update Posted (Actual)

March 29, 2023

Last Update Submitted That Met QC Criteria

March 27, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EudraCT: 2020-000855-11

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Systemic Inflammatory Response Syndrome

Clinical Trials on Methylprednisolone

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe